AudioCure Pharma – To turn incurable hearing loss into a treatable event
AudioCure Pharma focuses on the development of drug candidates, in particular on neurological disorders of the ear, including noise-induced hearing loss, ototoxicity, age-related hearing loss and tinnitus. All of these indications have a very high unmet clinical need. Our team of scientists are highly experienced specialists in the fields of neurosciences, audiology, drug development and clinical trials.
AudioCure Pharma is a biopharmaceutical company with a focus on hearing impairments. Our team of specialists is dedicated to the preclinical research and clinical development of novel pharmacotherapies or treat disorders of the inner ear.
Firstly, we are developing a treatment for acute noise-induced hearing loss; a disorder that is increasingly common as the world around us becomes noisier. Secondly, we are focus on acute tinnitus affecting more than 1% of the population each year.
Both these therapies are currently in the preclinical development stage. This field represents a huge opportunity as there are no FDA or EMA approved drugs for either indication.
The development for other disorders of the inner ear (including cochlear implant performance improvement and ototoxicity) as well as the vestibular system (e.g. dizziness and vertigo) will be initiated subsequently.
Learn more about our R&D here.